Legal Representation
Attorney
Christina M. Licursi
USPTO Deadlines
Next Deadline
1585 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20240528)
Due Date
May 28, 2030
Grace Period Ends
November 28, 2030
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
28 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| May 28, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED | Loading... |
| May 28, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Apr 25, 2024 | SUNA | E | NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED | Loading... |
| Apr 25, 2024 | CNPR | P | ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED | Loading... |
| Mar 29, 2024 | SUPC | I | STATEMENT OF USE PROCESSING COMPLETE | Loading... |
| Mar 7, 2024 | IUAF | S | USE AMENDMENT FILED | Loading... |
| Mar 29, 2024 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL | Loading... |
| Mar 7, 2024 | EISU | I | TEAS STATEMENT OF USE RECEIVED | Loading... |
| Dec 26, 2023 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Dec 26, 2023 | CHAN | I | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | Loading... |
| Dec 26, 2023 | COAR | I | TEAS CHANGE OF OWNER ADDRESS RECEIVED | Loading... |
| Nov 7, 2023 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Aug 31, 2023 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 29, 2023 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Aug 29, 2023 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 29, 2023 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Mar 7, 2023 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Jan 10, 2023 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Jan 10, 2023 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 21, 2022 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Dec 6, 2022 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Dec 6, 2022 | XAEC | I | EXAMINER'S AMENDMENT ENTERED | Loading... |
| Dec 6, 2022 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 6, 2022 | GNEA | F | EXAMINERS AMENDMENT E-MAILED | Loading... |
| Dec 6, 2022 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN | Loading... |
| Dec 1, 2022 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Jun 30, 2022 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Jun 20, 2022 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Encapsulated nucleic acids for use as biological therapeutics in gene therapy for the treatment of rare genetic disorders, cardiovascular diseases, respiratory diseases, infectious diseases, retinal diseases, metabolic disorders, hormonal deficiencies, endocrine diseases, eye diseases and disorders, intestinal diseases, autoimmune/autoinflammatory diseases, inflammatory disorders, musculoskeletal diseases, neurological disorders, hematologic conditions, cutaneous conditions, neurodegenerative diseases, congenital disorders, kidney and urinary diseases, reproductive diseases, mitochondrial diseases, lung disorders, immune system diseases, mouth diseases, digestive diseases
First Use Anywhere:
Oct 11, 2023
First Use in Commerce:
Oct 11, 2023
Classification
International Classes
005
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
Specific Disclaimer
"THERAPEUTICS"